» Articles » PMID: 26482044

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2015 Oct 21
PMID 26482044
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Most well-differentiated neuroendocrine tumors (WD-NET) of the enteropancreatic system are low-intermediate grade (G1, G2). Elevated proliferation demonstrated by either a brisk mitotic rate (>20/10 high power fields) or high Ki-67 index (>20%) defines a group of aggressive neoplasms designated as high-grade (G3) neuroendocrine carcinoma (NEC). High-grade NEC is equated with poorly differentiated NEC (PD-NEC) and is associated with a dismal outcome. Progression of WD-NETs to a high-grade neuroendocrine neoplasm very rarely occurs and their clinicopathologic and molecular features need to be characterized.

Experimental Design: We investigated 31 cases of WD-NETs with evidence of a component of a high-grade neoplasm. The primary sites included pancreas, small bowel, bile duct, and rectum. Histopathology of the cases was retrospectively reviewed and selected IHC and gene mutation analyses performed.

Results: The high-grade component occurred either within the primary tumor (48%) or at metastatic sites (52%). The clinical presentation, radiographic features, biomarkers, and the genotype of these WD-NETs with high-grade component remained akin to those of G1-G2 WD-NETs. The median disease-specific survival (DSS) was 55 months (16-119 months), and 2-year and 5-year DSS was 88% and 49%, respectively-significantly better than that of a comparison group of true PD-NEC (DSS 11 months).

Conclusions: Mixed grades can occur in WD-NETs, which are distinguished from PD-NECs by their unique phenotype, proliferative indices, and the genotype. This phenomenon of mixed grade in WD-NET provides additional evidence to the growing recognition that the current WHO G3 category contains both WD-NETs as well as PD-NECs.

Citing Articles

Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.

Joseph N, Umetsu S, Kim G, Terry M, Perry A, Bergsland E Endocr Pathol. 2024; 35(4):325-337.

PMID: 39556303 PMC: 11659342. DOI: 10.1007/s12022-024-09835-y.


Ectopic ACTH-Dependent Cushing's Syndrome Emerging at a Late Stage of a Mixed Histology Neuroendocrine Neoplasm: A Case Report.

Meyers M, Awada A, Karfis I, tKint de Roodenbeke D, Couvert H, Hanssens C Case Rep Oncol. 2024; 17(1):1146-1156.

PMID: 39474561 PMC: 11521454. DOI: 10.1159/000540707.


Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation.

Kasajima A, Pfarr N, Mayr E, Ura A, Moser E, von Werder A Endocr Pathol. 2024; 35(4):313-324.

PMID: 39382626 PMC: 11659366. DOI: 10.1007/s12022-024-09827-y.


Various Markers of Neuroendocrine Tumor: A Narrative Review.

Mukherjee S, Vagha S, Mukherjee M Cureus. 2024; 16(8):e67493.

PMID: 39314560 PMC: 11417284. DOI: 10.7759/cureus.67493.


Navigating the diagnostic gray zone: a challenging case of pancreatic high-grade neuroendocrine neoplasm.

Mullen B, Sy A, Dias Goncalves P, Zhang M Diagn Pathol. 2024; 19(1):123.

PMID: 39267076 PMC: 11391758. DOI: 10.1186/s13000-024-01546-6.


References
1.
Hochwald S, Zee S, Conlon K, Colleoni R, Louie O, Brennan M . Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002; 20(11):2633-42. DOI: 10.1200/JCO.2002.10.030. View

2.
Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder W . TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449(4):395-401. PMC: 1888719. DOI: 10.1007/s00428-006-0250-1. View

3.
Yachida S, Vakiani E, White C, Zhong Y, Saunders T, Morgan R . Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012; 36(2):173-84. PMC: 3261427. DOI: 10.1097/PAS.0b013e3182417d36. View

4.
Basturk O, Yang Z, Tang L, Hruban R, Adsay V, McCall C . The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015; 39(5):683-90. PMC: 4398606. DOI: 10.1097/PAS.0000000000000408. View

5.
Velayoudom-Cephise F, Duvillard P, Foucan L, Hadoux J, Chougnet C, Leboulleux S . Are G3 ENETS neuroendocrine neoplasms heterogeneous?. Endocr Relat Cancer. 2013; 20(5):649-57. DOI: 10.1530/ERC-13-0027. View